Back to Journals » Journal of Inflammation Research » Volume 13

Immunological Evaluation on Potential Treatment Window for Hospitalized COVID-19 Patients

Authors Yuan J, Kou S, Liang Y, Lan JF, Li X, Zeng L, Zou R, Liu Y, Liu L, Pan Y

Received 7 September 2020

Accepted for publication 16 October 2020

Published 24 November 2020 Volume 2020:13 Pages 985—993

DOI https://doi.org/10.2147/JIR.S280331

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Ning Quan


Jing Yuan,1,* Shanglong Kou,2,* Yanhua Liang,1 JianFeng Lan,1 Xiaohe Li,1 Lijiao Zeng,1 Rongrong Zou,1 Yingxia Liu,1 Lei Liu,1 Yanchao Pan1

1Diagnosis and Treatment of Infectious Disease Research Center, Shenzhen Third People’s Hospital, Shenzhen, Guangdong, People’s Republic of China; 2College of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou, Guangdong, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Yanchao Pan
Diagnosis and Treatment of Infectious Diseases Research Laboratory, Shenzhen Third People’s Hospital, Shenzhen 518112, People’s Republic of China
Tel +86 755-61222333
Fax +86 755-61238928
Email [email protected]

Purpose: Novel coronavirus disease has become such an escalating epidemic that the exponential growth of infected patients has overloaded the health-care systems in many countries. Determination of early assessments for patients with a risk of clinical deterioration would benefit the management of COVID-19 outbreaks.
Patients and Methods: A total of 214 confirmed COVID-19 patients were enrolled from January 11th to February 11th 2020. Medical records including laboratory parameters, clinical outcomes and other characteristics of the admitted patients were analyzed retrospectively.
Results: The critical patients experienced a significantly prolonged onset–admission interval and presented with lymphopenia (r=− 0.547, p=0.015) and lower albumin level (p< 0.001) 6 days after symptom onset. Early admission of critical patients significantly reduced the duration of hormone therapy. Starting from 9 days of hospital stay, the reduced lymphocyte counts exhibited linear growth. Furthermore, on days 9 and 12, significant correlations were demonstrated between immunological manifestations and duration of hormone therapy in critical patients, and length of hospital stay in severe patients. In addition, the virus negative conversion rate was more significantly correlated with increased lymphocytes in critical patients.
Conclusion: Early intervention, within 6 days of symptom onset, benefited patients’ recovery from critical illness. The 9– 12 days of hospital care represented a valuable window during which to evaluate the therapeutic effects on physical recovery and virus clearance.

Keywords: COVID-19, critical illness, potential window, length of hospital stay

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]